Skip to main content


Issue 20, Volume 4 - 2018

Volume 20, Number 4 - 2018

Table of Contents

Focal Therapy for Localized Prostate Cancer
[Rev Urol. 2018;20(4):143–144 doi: 10.3909/riu0823] © 2019 MedReviews®, LLC
Focal Ablation of Prostate Cancer Treatment Update
The challenge to the urology community is to reduce the risks of screening and treatment by reducing the number of men undergoing unnecessary biopsy and whole-gland curative treatment of low-risk disease. There is compelling evidence that focal ablation of prostate cancer is truly minimally invasive and offers major functional advantages over whole-gland treatment. [Rev Urol. 2018;20(3):145–157 doi: 10.3909/riu0809] © 2019 MedReviews®, LLC
Male Slings for Post-prostatectomy Incontinence Treatment Review
Stress urinary incontinence following radical prostatectomy can have a significant impact on a man’s quality of life. Male slings offer a perceived minimally invasive treatment option and do not require the manual dexterity necessary to operate an artificial urinary sphincter. In this review, we outline the history of male slings and discuss the various fixed and adjustable slings that are available on the market. It is important for the general urologist to understand the technical differences, outcomes, and common complications of suburethral slings. [Rev Urol. 2018;20(4):158–169 doi: 10.3909/riu080] © 2019 MedReviews®, LLC. This article is a US Government work and, as such, is in the public domain in the United States of America.
Nocturia: Finding an Identity
Nocturia is a condition that has a tremendous impact on a patient’s health and wellbeing. Getting up 2 or more times a night to urinate fragments sleep, preventing deep, restorative stages of the sleep cycle. With safer and more effective therapies, nocturia is a treatable condition that no longer should be overlooked. The simplicity of directly targeting the cause of nocturia, the overproduction of urine (ie, nocturnal polyuria) should be considered. Noctiva™ (desmopressin acetate) nasal spray (Avadel Pharmaceuticals plc, Chesterfield, MO), a novel FDA-approved microdose desmopressin nasal spray, can reduce nighttime urine production and potentially mitigate the potential harm of nocturia. [Rev Urol. 2018;20(4):170–173 doi: 10.3909/riu0822] © 2019 MedReviews®, LLC
Female Urethral Stricture NYU Case of the Month, September 2018
[Rev Urol. 2018;20(4):174–176 doi: 10.3909/riu0824A] © 2019 MedReviews®, LLC
Management of Ureteral Strictures NYU Case of the Month, October 2018
[Rev Urol. 2018;20(4):177–178 doi: 10.3909/riu0824B] © 2019 MedReviews®, LLC
Management of Testicular Cancer NYU Case of the Month, November 2018
[Rev Urol. 2018;20(4):179–181 doi: 10.3909/riu0824C] © 2019 MedReviews®, LLC